A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...
Medpage Today on MSN
OS Win for Enzalutamide in Prostate Cancer at High Risk for Biochemical Recurrence
BERLIN -- Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback